RecruitingRecruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT04665206 · Vivace Therapeutics, Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
About this study
Dose escalation (Part 1) will employ a traditional 3 + 3 design to assess safety of VT3989 in patients with metastatic solid tumors or mesothelioma. The 3 + 3 design will be implemented until the MTD or recommended phase 2 dose(s) and schedule(s) are determined. The MTD is defined as the highest dose level at which \< 33% of patients experience a dose limiting toxicity (DLT) during the first cycle of the study (Cycle 1).
Dose Expansion (Part 2) will further evaluate the safety and assess preliminary antitumor activity at the recommended phase 2 dose(s) and schedule(s) with up to 6 cohorts. Expansion cohorts 1 and 2 will enroll patients with mesothelioma of any site origin with or without NF2 mutations. Expansion cohort 3 will enroll non-pleural mesothelioma patients. Expansion cohort 4 will enroll solid tumor patients with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements. Cohort 5 will enroll pleural mesothelioma patients.
Combination part (Part 3) includes three cohorts. Cohort A will enroll mesothelioma patients who will receive VT3989 in combination with immunotherapy (nivolumab plus ipilimumab). Cohort B will enroll NSCLC patients whose tumors have exon 19 deletion or exon 21 L858R mutation and will receive VT3989 in combination with targeted therapy (Osimertinib). Cohort C will enroll pleural mesothelioma patients who will receive VT3989 in combination with chemotherapy (pemetrexed plus carboplatin).
Eligibility criteria
Inclusion Criteria:
* Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
* Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
* Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
* Part 1: Evaluable or measurable disease per RECIST v1.1 or mRECIST
* Part 2 and 3: Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
* ECOG: 0-1.
* Adequate organ functions, including the liver, kidneys, and hematopoietic system.
Exclusion Criteria:
* Active brain metastases or primary CNS (central nervous system) tumors.
* History of leptomeningeal metastases
* Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
* Known HIV positive or active Hepatitis B or Hepatitis C
* Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
* Corrected QT (QTcF) interval \> 470 msec (using Fridericia's correction formula).
* Additional active malignancy that may confound the assessment of the study endpoints
* Women who are pregnant or breastfeeding
* Unwilling or unable to use highly effective contraceptive measures.
* Prior treatment with TEAD inhibitor, except for EHE patients.
Study design
Enrollment target: 474 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2021-03-24
Estimated completion: 2030-03-02
Last updated: 2026-11-17
Interventions
Drug: VT3989Drug: Nivolumab & IpilimumabDrug: OsimertinibDrug: Pemetrexed/Carboplatin
Primary outcomes
- • Occurrence of Dose Limiting Toxicity (over the first 21 days of dosing)
- • Occurrence of General Toxicity (through study completion, an average of 30 months)
Sponsor
Vivace Therapeutics, Inc · industry
Contacts & investigators
ContactHeather Fritz · contact · hfritz@inclin.com · 650-627-7437
ContactNeelesh Sharma, MD · contact · nsharma@vivacetherapeutics.com · 732-476-4978
InvestigatorNeelesh Sharma, MD · study_director, Vivace Therapeutics
All locations (12)
UCSF Helen Diller Family Comprehensive Cancer CenterRecruiting
San Francisco, California, United States
University of Chicago Medical CenterRecruiting
Chicago, Illinois, United States
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
M Health Fairview University of Minnesota Medical CenterRecruiting
Minneapolis, Minnesota, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
NEXT OncologyRecruiting
San Antonio, Texas, United States
Virginia Cancer Specialists, PCRecruiting
Arlington, Virginia, United States
Monash HealthRecruiting
Clayton, Victoria, Australia
Peter MacCullum Cancer CentreRecruiting
Melbourne, Victoria, Australia
Linear Clinical ResearchTerminated
Nedlands, Western Australia, Australia